You are here: Home / Archives for Report

Global Engineering Services Industry Market Research Report Now Available from IBISWorld

April 24, 2012 By Leave a Comment


Los Angeles, CA (PRWEB) April 22, 2012

The global market for engineering services consists of the work performed by consultant engineering firms along with the in-house services undertaken by construction contractors, manufacturers, government agencies and utility owners. According to IBISWorld industry analyst Anthony Kelly, the industry’s performance is principally driven by the trends into construction, manufacturing and mining developments (particularly in the large industrial economies) and increasingly from work in the fields of technological development and the sustainable environment. Over the past decade the industry has expanded its operations by broadening across a wider range of multidisciplinary services, by the trend towards globalization and through the outsourcing of services by public authorities and major corporations.

The Global Engineering Services industry is one of the largest professional service industries, generating revenue of about $ 530 billion in 2012 (up 3.0% on the previous year), and employing 2.9 million people. Industry value added currently totals $ 318 billion, or 0.6% of the world’s GDP, two-thirds of which represents payments to employees and the balance the industry’s operating profit. The industry’s performance deteriorated during the late 2000s with the onset of recession in several of the largest developed economies and the subsequent decline in construction and industrial production. Despite the current improvement, industry revenue is estimated to average subdued growth by 0.5% per annum over the five years through 2012.

?International trade represents a significant share of industry activity (10.6% of revenue in 2012) and is mainly confined to relatively few large-scale consulting engineering firms that are capable of operating outside national boundaries,? said Kelly. A feature of the industry that has accompanied globalization has been the amalgamation of the larger players to achieve scale economies, broaden the market and strengthen the human and financial resources (consistent with the trend evident in other knowledge-based industries such as accounting, law, advertising and architecture).

The Global Engineering Services industry has a low concentration of ownership, with the four largest companies accounting for about 6.0% of annual industry revenue. The largest players in the global market for engineering services include URS Corporation, SNC-Lavalin Group, Bechtel Group, Jacobs Engineering Group, Fluor Corporation, AECOM Technology Corporation, CH2M HILL Companies, WS Atkins plc, and Altran Technologies. Despite this low concentration, there has been a trend over the past decade for the consolidation of the operations of many of the world’s leading consulting engineering firms, through mergers or strategic alliances. These large-scale, multidisciplined, multinational companies are well placed to win contracts in most markets. For more information, visit IBISWorld?s Global Engineering Services in the US industry report page.

Follow IBISWorld on Twitter: https://twitter.com/#!/IBISWorld

Friend IBISWorld on Facebook: http://www.facebook.com/pages/IBISWorld/121347533189

IBISWorld industry Report Key Topics

The industry comprises establishments engaged in applying physical laws and principles of engineering in the design, development and use of machines, materials, instruments, structures, processes and systems. The assignments may involve the provision of advice, preparation of feasibility studies, preparation of preliminary and final plans and designs, the provision of technical services on construction and project evaluation.

Industry Performance

Executive Summary

Key External Drivers

Current Performance

Industry Outlook

Industry Life Cycle

Products & Markets

Supply Chain

Products & Services

Major Markets

Globalization & Trade

Business Locations

Competitive Landscape

Market Share Concentration

Key Success Factors

Cost Structure Benchmarks

Barriers to Entry

Major Companies

Operating Conditions

Capital Intensity

Key Statistics

Industry Data

Annual Change

Key Ratios

About IBISWorld Inc.

Recognized as the nation?s most trusted independent source of industry and market research, IBISWorld offers a comprehensive database of unique information and analysis on every US industry. With an extensive online portfolio, valued for its depth and scope, the company equips clients with the insight necessary to make better business decisions. Headquartered in Los Angeles, IBISWorld serves a range of business, professional service and government organizations through more than 10 locations worldwide. For more information, visit http://www.ibisworld.com or call 1-800-330-3772.







Related Wellness Press Releases

Filed Under: Wellness Tagged With: , , , , , , , , ,

Global Neurodegenerative Drugs Market to Exceed $43.4 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

March 23, 2012 By Leave a Comment

San Jose, CA (PRWEB) April 12, 2010

Neurodegenerative diseases, caused due to neuron deficiency or dysfunction of the spinal cord or brain cells, are destructive in nature, as regeneration of affected cells is not possible and results in ultimate damage or death. Major neurodegenerative diseases with significant unmet medical needs include Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington’s disease. There are only a few treatment available for some of these diseases, and several of these treatment options provide only symptomatic relief. For a few others such as the Huntington’s disease, there is still not a single therapy available that can treat the disease.

The United States dominates the world neurodegenerative drugs market as stated by the new market research report on Neurodegenerative Drugs market. The market exhibits huge potential considering the high rates of prevalence of Alzheimer’s and Parkinson’s disease. The market is largely untapped due to under-diagnosis owing to lack of proper diagnostics, and lack of therapies that can effectively and safely prevent or treat the diseases.

Multiple Sclerosis represents the largest segment of the neurodegenerative drugs market. The multiple sclerosis drugs market is all set for a major transformation with new drugs in pipeline awaiting approval in near future. Most pipeline drugs are showing promising results in terms of reducing disease progression and other end-points compared to existing drugs. The most promising multiple sclerosis candidates include oral therapies such as Sanofi-aventis’ Teriflunomide, Active Biotech’s Laquinimod, Merck’s Cladribine and Novartis’ FTY720.

Alzheimer’s is the fastest growing segment of the neurodegenerative drugs market. The currently available drugs for Alzheimer’s disease not only provide limited efficacy, but may also result in serious adverse effects. There are issues with acceptability and safety, and some patients may even fail to respond to treatment with available drugs. The outlook appears interesting considering that a few leading products are lined up for patent expiry, including Namenda and Exelon, while there are others in pipeline that promise to deliver on the failure of available therapies.

Key players profiled in the report include Amarin Corporation Plc; AstraZeneca Plc; Avanir Pharmaceuticals Inc.; Avigen Inc.; Bayer Schering Pharma AG; Boehringer Ingelheim GmbH; Biogen Idec Inc.; Bristol-Myers Squibb Co.; Biovail Corporation; Ceregene, Inc.; Eisai, Inc.; Elan Pharmaceuticals; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline plc; H. Lundbeck A/S; Merz Pharmaceuticals GmbH; Merck Serono; Mitsubishi Tanabe Pharma Corporation; Neurologix, Inc.; NeuroSearch A/S; Novartis AG; Pfizer Inc.; Sanofi-aventis S.A.; Shire Pharmaceuticals Group Plc; Teva Pharmaceutical Industries Limited; Valeant Pharmaceuticals International; and Wyeth Pharmaceuticals, Inc.

The report titled “Neurodegenerative Drugs: A Global Strategic Business Report” announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, market drivers, market inhibitors, competitive scenario, clinical trials, product introductions/approvals, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe and Rest of World. The study analyzes market data and analytics in terms of value sales for neurodegenerative drugs by disease type, including Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Other Diseases.

For more details about this comprehensive market research report, please visit -

http://www.strategyr.com/Neurodegenerative_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone 408-528-9966

Fax 408-528-9977

Web Site http://www.StrategyR.com/

###





Find More Alzheimer Disease Press Releases

Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , , , ,

Scientists Report Key Finding in Breast Cancer Research

March 21, 2012 By Leave a Comment


Philadelphia, PA (Vocus) April 17, 2010

Researchers at Drexel University College of Medicine have discovered that a certain type of sugar found naturally in the body is elevated in breast cancer cells and is critical for cancer growth and movement. When researchers reduced and normalized the levels of this sugar, they were able to slow the growth of the cancer cells and block invasion. The findings, published in the March 1 issue of Oncogene, represent a potential new therapeutic target for treating aggressive forms of breast cancer.

Scientists have known for years that cancer cells are addicted to sugar. Compared to neighboring normal cells, cancer cells take up nearly ten times more sugar. The cancer cells use the increased sugar levels to fuel rapid cell growth and spread. The Drexel researchers studied a particular sugar-based protein modification known as O-GlcNAc. Alterations in this modification have been linked previously to diabetes and Alzheimer?s disease, but not to cancer.

?This sugar, O-GlcNAc, is used inside cells to tag proteins and alter their function,? said lead author Mauricio J. Reginato, Ph.D., assistant professor in the Department of Biochemistry and Molecular Biology at Drexel University College of Medicine. ?We think this is a very exciting discovery because this may be one way that cancer cells use the increased sugar to regulate key pathways that control growth and invasion.?

Reginato and his colleagues studied established cells from patients with estrogen-independent breast cancer, the most aggressive form of the disease, which does not respond well to current treatments. The researchers found that compared to normal mammary cells, all the breast cancer cells contained elevated levels of O-GlcNAc, as well as increased levels of the enzyme responsible for adding this sugar to protein.

When they reduced the levels of the O-GlcNAc enzyme, or blocked its activity with a drug, they reduced the growth of breast cancer and also blocked the invasion. In addition, by reducing the enzyme levels, they also reduced levels of a protein known as FoxM1, which is known to play a critical role in controlling cancer growth and spread.

The Drexel researchers and collaborators are now working to develop more potent chemicals to target the O-GlcNAc enzyme, a potential new therapeutic target for treating breast cancer and possibly other cancers.

?We looked at cancer databases and found that this enzyme is also elevated in other types of cancers.? said Reginato. ?Our next step will be to study those cancers more closely to determine if we can achieve the same effect.?

About Drexel University College of Medicine

Drexel University College of Medicine has established some of the most highly innovative and rigorous academic programs available today, incorporating the University?s expertise in engineering and technology into traditional medical training. The College of Medicine is home to one of the nation?s leading centers for spinal cord research; one of the foremost centers for malaria study; and a highly regarded HIV/AIDS program with extensive NIH-funded research in prevention and therapeutic interventions. Drexel University College of Medicine has been designated a Vanguard National Center of Excellence in Women?s Health by the U.S. Department of Health & Human Services, and is highly respected in numerous other specialties including autism, cardiology, minimally invasive surgery, and toxicology. Visit http://www.drexelmed.edu for more information.

Media Contact:

Rachel Sparrow,

215-255-7328

###





Find More Alzheimer Disease Press Releases

Filed Under: Alzheimer's Disease Tagged With: , , , , ,

American Association of Poison Control Centers Releases Annual Poison Exposure Report

December 24, 2011 By Leave a Comment

Alexandria, VA (PRWEB) December 21, 2011

America?s 57 poison centers fielded 3.9 million calls in 2010, an average of nearly 11,000 per day, according to the recently published 2010 Annual Report of the American Association of Poison Control Centers? National Poison Data System. The 28th annual report was published in the December 2011 issue of Clinical Toxicology.

The American Association of Poison Control Centers (AAPCC) maintains the National Poison Data System (NPDS), a large database containing information about all poison exposure phone calls to every poison center across the country. NPDS is the only near real-time, comprehensive poisoning surveillance database in the United States.

According to the report, poison experts at the nation?s poison centers treated 2.4 million human poison exposures and handled 1.5 million information calls in 2010. Children younger than 6 accounted for about half of all the poison exposure calls; however, adults 20 and older accounted for 92 percent of all deaths reported.

A total of 1,730 deaths were reported in 2010; of those, 139 were younger than 20, including 55 younger than 6. Sedatives/hypnotics/antipsychotics, cardiovascular drugs, opioids, and acetaminophen combinations were most frequently associated with poison-related deaths.

Poison exposures with serious outcomes increased 4.5 percent over the previous year. Eighty-one percent of poisonings were unintentional, and 15 percent were intentional. Of the 15 percent, 9 percent were suspected suicides.

?Poisonings continue to be a significant cause of illness and death in the U.S.,? said Alvin C. Bronstein, M.D., lead author of the report. ?The NPDS provides a nationwide infrastructure for public health surveillance of poison exposures, including drug, consumer product, environmental and food poisoning. This report supports the value of poison centers and the need for specialized medical toxicology expertise across the country.?

The 2010 report also highlights the vital role of poison centers in the nation?s public health system. For example, poison centers tracked the health impact of the 2010 Gulf of Mexico oil spill and raised the alarm about the emerging public health threats of designer amphetamines (Bath Salts) and designer marijuana (Spice and variants).

?The ability of the NPDS to track emerging public health threats makes it a valuable, vital, model system for national and global public health,? said Richard C. Dart, M.D., Ph.D., AAPCC president. ?When someone calls a poison center, information about that poison exposure is uploaded to the NPDS within 20 minutes. Because the data is so current, poison centers are often the first to identify contaminated food outbreaks, tainted medication, drug abuse threats or other emerging public health crises.?

Other findings in the report include:

About 75 percent of all calls to poison centers originated in people?s homes.
About 71 percent of the 2.4 million people who called with poison emergencies were treated at home, saving millions of dollars in medical expenses.
The top five substances most frequently involved in human poisonings were analgesics (11.5%), cosmetics/personal care products (7.7%), household cleaning substances (7.3%), sedatives/hypnotics/antipsychotics (6%) and foreign bodies/toys/miscellaneous (4.2%).

?This report comes at a time when poison centers across the country are facing budget crises and underscores the valuable service poison centers provide,? said Deborah Carr, M.Ed., AAPCC executive director. ?America?s system of 57 poison control centers is one of the most successful and cost-effective public health programs in the nation. Poison centers save countless American lives and millions of American taxpayer dollars every year.?

The 28th annual report issued by the American Association of Poison Control Centers is available at http://www.aapcc.org. The report was authored by Drs. Alvin C. Bronstein, Daniel A. Spyker, Louis R. Cantilena Jr., Jody L. Green, Barry H. Rumack and Richard C. Dart.

For more information, the media may contact Loreeta Canton, AAPCC communications manager, at 703.894.1863 or canton(at)aapcc(dot)org.

The AAPCC supports the nation?s 57 poison centers in their efforts to treat and prevent drug, consumer product, animal, environmental and food poisoning. Members staff the Poison Help hotline at 1-800-222-1222 that provides free, confidential, expert medical advice 24 hours a day, seven days a week, 365 days a year from toxicology specialists, including nurses, pharmacists, physicians and poison information providers. In addition, the AAPCC maintains the only poison information and surveillance database in the United States, providing real-time monitoring of unusual poisoning patterns, chemical exposures and other emerging public health hazards. The AAPCC partners with federal agencies such as HRSA and CDC, as well as private industry.

To learn more, visit http://www.aapcc.org, like us on Facebook, follow us on Twitter, or read our blog at aapcc.wordpress.com.

###





Filed Under: Wellness Tagged With: , , , , , , , ,

Global Genetic Testing Market to Reach US$1.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

November 30, 2011 By Leave a Comment

San Jose, CA (Vocus/PRWEB) January 11, 2011

Genetic testing represents the most rapidly expanding segment of the molecular diagnostics market worldwide. Molecular diagnostics is the fastest growing segment in the In-Vitro Diagnostics (IVD) market. Key factors fostering growth in the molecular diagnostics market include increasing awareness about human genome, newer technologies and innovation for accurate detection and faster screening. With increasing number of aging population globally, countries across the world face the challenge of preventing age-related diseases, such as cardiovascular diseases and diabetes. This indicates the requirement of new diagnostics, including genetic testing. Genetic testing, which of-late has been transforming itself from service-driven to product-driven market, is expected to provide an impetus to diagnostic companies for the expansion of their operations. Advancements in genetic testing field enable physicians to determine patients? health at different stages of the diagnostic treatment process.

Growing incidence of genetic diseases unravels new opportunities for genetic testing. The market is likely to expand for screening the newborns, diagnosing rare and fatal disorders, and predicting the probability of occurrence of diseases, such as Huntington. Genetic tests for newborn screening are expected to expand immensely over the coming years. In addition, with advances in genetic testing procedures, tests would be focused on early detection of Alzheimer disease, hemochromatosis, breast cancer, colorectal cancer, diabetes in young people, and rare forms of amyotrophic lateral sclerosis. Genetic testing identifies finest cancer treatment for specific patients. Advancements in genetic testing, together with genetically engineered drugs, are expected to aid in tailoring personalized medicine for specific races, individuals, and families.

The US represents the largest market for genetic testing worldwide, as stated by the new market research report on Genetic Testing. Genetic counseling services are on the rise, specifically in the US. Presently, there are around 2,780 certified genetic counselors operating in the United States. Direct-to-Consumer genetic testing is expected to open new avenues in the US, for companies looking for areas to further expand their range of screening tests. DTC genetic testing method involves marketing genetic tests directly to consumers without involvement of independent healthcare provider.

The US is witnessing dramatic changes in the DNA-based testing industry, with the advent of transformational technologies, which are extending the scope of complicated genomic and genetic testing into clinical and medical laboratories, which conduct tests on individual patients for identifying genes linked to certain medical disorders.

Major players profiled in the report include Abbott Laboratories, Abbott Molecular Inc., Applied Biosystems Inc., AutoGenomics, Inc., BioRad Laboratories, Celera Group, Clinical Data Inc., Orchid Cellmark Inc., PerkinElmer Inc., Quest Diagnostics Inc., Roche Diagnostics Corp., Roche Molecular Diagnostics Inc. among others.

The research report titled “Genetic Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the genetic testing market, current market trends, key growth drivers, new product innovations/launches, recent industry activity, and profiles of major/niche global market participants. The report provides annual sales estimates and projections for the global genetic testing market for the years 2007 through 2015 for the regions, including US, Canada, Japan, Europe, and Rest of World. The report also analyzes the US market for genetic testing by application type – Pharmacogenomic Testing, Prenatal and Newborn Genetic Testing, and Predictive Medicine. Also, a seven-year (2000-2006) historic analysis is provided for additional market perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Genetic_Testing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

# # #





Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , , , ,

Global Genetic Testing Market to Reach US$1.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

November 29, 2011 By Leave a Comment

San Jose, CA (Vocus/PRWEB) January 11, 2011

Genetic testing represents the most rapidly expanding segment of the molecular diagnostics market worldwide. Molecular diagnostics is the fastest growing segment in the In-Vitro Diagnostics (IVD) market. Key factors fostering growth in the molecular diagnostics market include increasing awareness about human genome, newer technologies and innovation for accurate detection and faster screening. With increasing number of aging population globally, countries across the world face the challenge of preventing age-related diseases, such as cardiovascular diseases and diabetes. This indicates the requirement of new diagnostics, including genetic testing. Genetic testing, which of-late has been transforming itself from service-driven to product-driven market, is expected to provide an impetus to diagnostic companies for the expansion of their operations. Advancements in genetic testing field enable physicians to determine patients? health at different stages of the diagnostic treatment process.

Growing incidence of genetic diseases unravels new opportunities for genetic testing. The market is likely to expand for screening the newborns, diagnosing rare and fatal disorders, and predicting the probability of occurrence of diseases, such as Huntington. Genetic tests for newborn screening are expected to expand immensely over the coming years. In addition, with advances in genetic testing procedures, tests would be focused on early detection of Alzheimer disease, hemochromatosis, breast cancer, colorectal cancer, diabetes in young people, and rare forms of amyotrophic lateral sclerosis. Genetic testing identifies finest cancer treatment for specific patients. Advancements in genetic testing, together with genetically engineered drugs, are expected to aid in tailoring personalized medicine for specific races, individuals, and families.

The US represents the largest market for genetic testing worldwide, as stated by the new market research report on Genetic Testing. Genetic counseling services are on the rise, specifically in the US. Presently, there are around 2,780 certified genetic counselors operating in the United States. Direct-to-Consumer genetic testing is expected to open new avenues in the US, for companies looking for areas to further expand their range of screening tests. DTC genetic testing method involves marketing genetic tests directly to consumers without involvement of independent healthcare provider.

The US is witnessing dramatic changes in the DNA-based testing industry, with the advent of transformational technologies, which are extending the scope of complicated genomic and genetic testing into clinical and medical laboratories, which conduct tests on individual patients for identifying genes linked to certain medical disorders.

Major players profiled in the report include Abbott Laboratories, Abbott Molecular Inc., Applied Biosystems Inc., AutoGenomics, Inc., BioRad Laboratories, Celera Group, Clinical Data Inc., Orchid Cellmark Inc., PerkinElmer Inc., Quest Diagnostics Inc., Roche Diagnostics Corp., Roche Molecular Diagnostics Inc. among others.

The research report titled “Genetic Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the genetic testing market, current market trends, key growth drivers, new product innovations/launches, recent industry activity, and profiles of major/niche global market participants. The report provides annual sales estimates and projections for the global genetic testing market for the years 2007 through 2015 for the regions, including US, Canada, Japan, Europe, and Rest of World. The report also analyzes the US market for genetic testing by application type – Pharmacogenomic Testing, Prenatal and Newborn Genetic Testing, and Predictive Medicine. Also, a seven-year (2000-2006) historic analysis is provided for additional market perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Genetic_Testing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

# # #





Related Alzheimer Disease Press Releases

Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , , , ,

Global Genetic Testing Market to Reach US$1.8 Billion by 2015, According to a New Report by Global Industry Analysts, Inc.

November 29, 2011 By Leave a Comment

San Jose, CA (Vocus/PRWEB) January 11, 2011

Genetic testing represents the most rapidly expanding segment of the molecular diagnostics market worldwide. Molecular diagnostics is the fastest growing segment in the In-Vitro Diagnostics (IVD) market. Key factors fostering growth in the molecular diagnostics market include increasing awareness about human genome, newer technologies and innovation for accurate detection and faster screening. With increasing number of aging population globally, countries across the world face the challenge of preventing age-related diseases, such as cardiovascular diseases and diabetes. This indicates the requirement of new diagnostics, including genetic testing. Genetic testing, which of-late has been transforming itself from service-driven to product-driven market, is expected to provide an impetus to diagnostic companies for the expansion of their operations. Advancements in genetic testing field enable physicians to determine patients? health at different stages of the diagnostic treatment process.

Growing incidence of genetic diseases unravels new opportunities for genetic testing. The market is likely to expand for screening the newborns, diagnosing rare and fatal disorders, and predicting the probability of occurrence of diseases, such as Huntington. Genetic tests for newborn screening are expected to expand immensely over the coming years. In addition, with advances in genetic testing procedures, tests would be focused on early detection of Alzheimer disease, hemochromatosis, breast cancer, colorectal cancer, diabetes in young people, and rare forms of amyotrophic lateral sclerosis. Genetic testing identifies finest cancer treatment for specific patients. Advancements in genetic testing, together with genetically engineered drugs, are expected to aid in tailoring personalized medicine for specific races, individuals, and families.

The US represents the largest market for genetic testing worldwide, as stated by the new market research report on Genetic Testing. Genetic counseling services are on the rise, specifically in the US. Presently, there are around 2,780 certified genetic counselors operating in the United States. Direct-to-Consumer genetic testing is expected to open new avenues in the US, for companies looking for areas to further expand their range of screening tests. DTC genetic testing method involves marketing genetic tests directly to consumers without involvement of independent healthcare provider.

The US is witnessing dramatic changes in the DNA-based testing industry, with the advent of transformational technologies, which are extending the scope of complicated genomic and genetic testing into clinical and medical laboratories, which conduct tests on individual patients for identifying genes linked to certain medical disorders.

Major players profiled in the report include Abbott Laboratories, Abbott Molecular Inc., Applied Biosystems Inc., AutoGenomics, Inc., BioRad Laboratories, Celera Group, Clinical Data Inc., Orchid Cellmark Inc., PerkinElmer Inc., Quest Diagnostics Inc., Roche Diagnostics Corp., Roche Molecular Diagnostics Inc. among others.

The research report titled “Genetic Testing: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the genetic testing market, current market trends, key growth drivers, new product innovations/launches, recent industry activity, and profiles of major/niche global market participants. The report provides annual sales estimates and projections for the global genetic testing market for the years 2007 through 2015 for the regions, including US, Canada, Japan, Europe, and Rest of World. The report also analyzes the US market for genetic testing by application type – Pharmacogenomic Testing, Prenatal and Newborn Genetic Testing, and Predictive Medicine. Also, a seven-year (2000-2006) historic analysis is provided for additional market perspective.

For more details about this comprehensive market research report, please visit ? http://www.strategyr.com/Genetic_Testing_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world?s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1200 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

# # #





Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , , , ,

Global Wine Market to Reach 26.12 Billion Liters by 2015, According to a New Report by Global Industry Analysts, Inc.

November 18, 2011 By Leave a Comment

San Jose, California (Vocus/PRWEB) February 11, 2011

Wine, the niche category in the alcoholic beverages market is headed towards a healthy future with a steady growth forecast over the review period. The underlying health benefits of wine would also enable the segment to encroach the markets of beer and spirit, the other two segments. Recent research findings confirm the fact that moderate consumption of wine prevents heart disease, cancer, Alzheimer?s disease as well as muscular degeneration. High publicity received by these findings is spurring consumption of wine at home and at horeca (hotels, restaurants and cafes) outlets, particularly in non-wine producing countries. Developing countries like Russia, China, Australia and India, to name a few, are expected to drive future growth in the market. Changing lifestyles in these countries, which mostly mimic Western lifestyles, is proving to be a major win for the growth in wine consumption. Previously, interest in wines was confined to middle-aged customers, today a growing base of younger consumers are exhibiting a marked preference for wine over other alcoholic beverages.

New players entering the market and greater focus and investments in advertising and marketing campaigns intensified competition in the market place. The market has witnessed an unprecedented increase in wine sales through the Internet over the past few years. Although conventional wine producing European countries such as France, Spain and Italy still dominate the global market, they are facing stiff competition from new world wine regions like China and Australia, to name a few, which are progressing at a rapid pace with large-scale production, clever marketing strategies and competitive pricing. Regions including the US, Australia, Chile, New Zealand, South Africa and Argentina increased their combined share in the world market from 23% in 2005 to 30% by the end of 2008. With the availability of improved, latest technical know-how and equipment the new world regions are able to consistently produce good quality wines. Presently, the market is reeling under intense price pressures, triggered by rising competition and global oversupply.

The global market for wine witnessed a slowdown in growth during the recessionary years 2008 and 2009. The economic crisis and the subsequent deceleration in consumption, which added to the already existing problem of over production, adversely affected the global wine industry. The sharp decline was primarily attributed to a drastic reduction in consumption in the European Union, the largest market for wines worldwide. Maximum declines were witnessed in Spain and France while outside Europe, it was the US that recorded the highest decline. Developed markets of the US and Europe were more affected than the emerging markets of Asia-Pacific, Latin America, Eastern Europe and Australasia. During 2009, global grape production also fell. Segment wise, Champagne recorded the highest decline in volume as well as value sales in 2009. Champagne exports declined by 45% in terms of value and 40% in terms of volume during 2009. While the world?s major wine consuming region, Europe takes a back seat with consumption in major countries, such as France, slowing down, Asia-Pacific, driven by China is poised to grab large chunk of Europe?s share in the foreseeable future. The economic downturn also led to the trend of consumers readily trading down to cheaper wine varieties, shunning the more exclusive, expensive wines.

The wine industry reverted back on the path of gradual recovery, beginning 2010, with improved revival trends reported by global suppliers. Despite poor harvests in some of the major supplying nations, the average per bottle price managed to show improvement. The year 2010 also witnessed improvements in the export and import scenario in line with the improving global economy.

Europe positions itself as the single largest consumer and producer of wines, amassing a lion?s share of the worldwide market, as stated by the new research report on Wine. European countries including France, Spain and Italy capture the majority share of wine production in the region. Next to Europe, the US and Asia-Pacific rank as the other most significant wine consumers and producers worldwide. Wine industry in Asia-Pacific remained buoyant even during the volatile economic recession, and is projected to register the overall fastest growth both in terms of volume and value terms through 2015. The rapidly emerging economy in the region, China, is slated to witness an unprecedented increase in wine consumption and is poised to become a major contender in the global wine industry in future. By product group, the Still Wine category completely dominates the wine market in terms of sheer size. However, with respect to growth pace, Fortified Wine segment is expected to lead the way for the assessment period 2007-2015.

Key participants profiled in the report include Bacardi Limited, Brown-Forman Corporation, Castel Group, Constellation Brands Inc., Robert Mondavi Winery, Constellation Wines Australia, E.&J. Gallo Winery, Kendall-Jackson Wine Estates Ltd, Lanson BCC, Maison Burtin, LVMH Mo

Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , , , ,

Alzheimer’s Disease Cutting Edge Research Announced on Natural Health News Report Website

September 25, 2011 By Leave a Comment

Boca Raton, Fla. (PRWEB) November 14, 2008

It’s one of the most debilitating diseases known to man, and new findings about Alzheimer’s disease have just been posted on the Natural Health News Report website (http://www.naturalhealthnewsreport.com/). A compound found in red wine and grapes may counter a hallmark of the disease.

According to the website, Dr. Philippe Marambaud of the Litwin-Zucker Research Center for the Study of Alzheimer’s Disease and Memory Disorders in New York, says lab tests show that Resveratrol, a non-flavonoid polyphenol found in red wines, hampered beta-amyloid protein. That protein is a key ingredient in plaque found in the brains of people who die with Alzheimer’s disease. Resveratrol didn’t stop the protein’s production, but instead, it encouraged beta amyloid’s breakdown.

Dr. Marambaud and his colleagues also tested a handful of other antioxidants against beta-amyloid. Only Resveratrol stood out. In addition, he adds that Resveratrol has been shown to have some “very interesting pharmacological effects” against herpes, some cancers, and possibly neurodegenerative diseases such as Huntington’s.

Marambaud’s interest was sparked by observational studies (done by other experts) showing that Alzheimer’s is rarer in populations that consume moderate amounts of red wine.

In fact, in France for example, many people are living longer lives despite a diet high in saturated fat. This phenomenon has been labeled the “French Paradox.” Researchers believe that red wine intake can help prevent certain Cancers, heart disease and Alzheimer’s disease.

In addition, Natural Health News Report also has the latest information on a new experimental drug that many have high hopes in the fight against Alzheimer’s disease. Unlike many drugs already on the market that just treat the symptoms, this new pill may stop the progression of the disease by breaking up the protein tangles that clog victims’ brains.

To read the entire report about the latest in these cutting edge research results, visit http://www.naturalhealthnewsreport.com/rept/report0005.pdf?x=webb0201

About Natural Health News Report

Natural Health News Report offers the latest research and trends on the most dangerous diseases and their treatments. Topics addressed include Alzheimer’s Disease, heart disease, cancer, men’s health issues, and many others. Natural Health News Reports is not a substitute for your physician’s advice, but is offered as a source of information for helping people fight disease and live longer, healthier lives.

MEDIA CONTACT:

Bruce Serbin

Reeves Laverdure PR

bserbin @ reevespr.com

561-391-8717

http://www.reevespr.com

###





Related Alzheimer Disease Press Releases

Filed Under: Alzheimer's Disease Tagged With: , , , , , , , , , ,

New MedPredict Report Reveals Top Alzheimer?s Experts? Insights on Diagnostics and Treatments in Pipeline

September 11, 2011 By Leave a Comment

(PRWEB) June 2, 2010

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled ?Thought Leader Insight & Analysis: Alzheimer?s Disease,? designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in this disease area.

MedPredict interviewed renowned Alzheimer?s disease thought leaders to identify the most promising candidates in clinical development, as well as explore unmet needs.

?In this report, our expert panel describes the clinical progress of the most interesting therapeutic and diagnostic candidates in the pipeline,? according to Jeff Berk, MedPredict?s president and lead author of this report. ?The panel covers active and passive immunologic approaches and targeted therapies that will improve outcomes in the prevention and treatment of Alzheimer?s disease and mild cognitive impairment.?

MedPredict?s Thought Leader Panel ranks the most promising small molecules and antibodies that are targeting amyloid and plaques, offering their opinions on gamma-secretase inhibitors and modulators, beta-secretase inhibitors, Tau inhibitors, cardiovascular agents, anti-amyloids and aggregation inhibitors, mTOR inhibitors, SIRT-1, Liver X, metal chelators and drugs specifically designed to enhance mental function.

?Physicians who treat Alzheimer?s disease face multiple challenges in their effort to improve the lives of patients who have or will have dementia,? said Berk. ?Just as a cardiologist would do to prevent a heart attack in a patient with high blood pressure and high cholesterol, the neurologist or gerontologist must be able to identify people who are at risk of developing mild cognitive impairment and progressing on to Alzheimer?s disease, and treat them prophylactically. For patients with more advanced disease, new therapies are needed to slow degeneration, enhance cognitive function and protect the remaining neuronal structure. For both symptomatic and asymptomatic patients, diagnostics are needed to track the effectiveness of these new therapeutics.?

Companies/partnerships discussed in this report: Abbott, Allon, Astellas/CoMentis, Ariad, AstraZeneca/Banner, AstraZeneca/Takeda, AstraZeneca, Avid, Baxter, Bayer-Schering/Avid, Boehringer Ingelheim/Ablynx, Bristol-Myers Squibb, Ceregene, Elan/Transition Therapeutics/AstraZeneca, Elan/Johnson & Johnson/Pfizer, Eisai, GE Healthcare, GlaxoSmithKline, Lilly, Lilly/Elan, Merck, Noscira/Zeltia, Novartis, Pfizer, Pfizer/Medivation, Prana, TauRx, and Transtech/Pfizer.

The full report may be purchased by contacting MedPredict.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.

For more information contact:

Elizabeth Mathews

MedPredict

513.271.1924

liz (at) medpredict (dot) com

###





More Alzheimer Disease Press Releases

Filed Under: Alzheimer's Disease Tagged With: , , , , , , , ,
« Older Posts